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A B S T R A C T We have previously reported that vir-
ulent egg yolk-grown Legionella pneumophila, Phil-
adelphia 1 strain, multiplies intracellularly in human
blood monocytes and only intracellularly under tissue
culture conditions. In this paper, we have investigated
the effect of erythromycin and rifampin on L. pneu-
mophila-monocyte interaction in vitro; erythromycin
and rifampin are currently the drugs of choice for the
treatment of Legionnaires' disease.
The intracellular multiplication of L. pneumophila
is inhibited by erythromycin and rifampin, as mea-
sured by colony-forming units, whether the antibiotics
are added just before or just after infection of mono-
cytes with L. pneumophila, or 2 d after infection when
L. pneumophila is in the logarithmic phase of growth
in monocytes. Intracellular multiplication of L. pneu-
mophila is inhibited by 1.25 ,tg/ml but not <0.125
,ig/ml erythromycin and 0.01 ,ug/ml but not <0.001
,tg/ml rifampin. These concentrations of antibiotics
are comparable to those that inhibit extracellular mul-
tiplication of L. pneumophila under cell-free condi-
tions in artificial medium; the minimal inhibitory con-
centration is 0.37 Ag/ml for erythromycin and 0.002
,gg/ml for rifampin. Multiplication of L. pneumophila
in the logarithmic phase of growth in monocytes is
inhibited within 1 h of the addition of antibiotics. In-
tracellular bacteria inhibited from multiplying by an-
tibiotics are not killed. By electron microscopy, the
bacteria appear intact within membrane-bound vac-
uoles, studded with ribosomelike structures.
L. pneumophila multiplying extracellularly on ar-
tificial medium is killed readily by relatively low con-
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centrations of erythromycin and rifampin; the mini-
mal bactericidal concentration is 1 ,tg/ml for eryth-
romycin and 0.009 ,ug/ml for rifampin. In contrast,
L. pneumophila multiplying intracellularly is resistant
to killing by these concentrations of erythromycin and
rifampin or by concentrations equal to or greater than
peak serum levels in humans. Extracellular L. pneu-
mophila in stationary phase is also resistant to killing
by erythromycin and rifampin. These findings, taken
together with our previous work, indicate that, in vivo,
L. pneumophila is resistant to killing by erythromycin
and rifampin.
Inhibition of L. pneumophila multiplication in
monocytes by antibiotics is reversible; when the an-
tibiotics are removed from infected monocyte cultures
after 2 d, L. pneumophila resumes multiplication.
This study indicates that patients with Legionnaires'
disease under treatment with erythromycin and rifam-
pin require host defenses to eliminate L. pneumophila,
and that inadequate host defenses may result in relapse
after cessation of therapy.
I NTRODUCTION
We have previously reported that Legionella pneu-
mophila, the agent of Legionnaires' disease, is a fac-
ultative intracellular pathogen. The bacteria multiply
intracellularly in human monocytes and alveolar mac-
rophages, and, under tissue culture conditions, mul-
tiplication is exclusively intracellular (1, 2). Virulent
in vivo grown L. pneumophila is completely resistant
to the bactericidal effects of human serum, even in the
presence of high titer anti-L. pneumophila antibody
(3). The bacteria also resist killing by human poly-
morphonuclear leukocytes (PMN) even in the presence
of specific antibody and complement (3, 4). Antibody
and complement promote the binding of L. pneu-
mophila to monocytes, but do not inhibit the rate of
bacterial multiplication in monocytes (4). In vitro ac-
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tivated human monocytes and alveolar macrophages
do inhibit the intracellular multiplication of L. pneu-
mophila (2, 5).
Erythromycin and rifampin are currently the drugs
of choice for the treatment of Legionnaires' disease.
Both clinical experience and in vivo studies indicate
that these antibiotics are efficacious in treating Le-
gionnaires' disease (6-9). L. pneumophila grown un-
der cell-free conditions on artificial media is inhibited
from multiplying by these antibiotics and is killed by
concentrations of these antibiotics that are the same
or somewhat higher than the minimal inhibitory con-
centration (MIC)' (10, 11).
In this study, we have examined the effect of eryth-
romycin and rifampin on L. pneumophila located in-
tracellularly in human monocytes. We shall demon-
strate (a) that these antibiotics rapidly inhibit the in-
tracellular multiplication of L. pneumophila at
concentrations comparable to those that inhibit L.
pneumophila multiplication under cell-free conditions
in artificial medium; (b) that L. pneumophila multi-
plying in human monocytes is resistant to killing by
concentrations of erythromycin and rifampin that are
bactericidal to L. pneumophila multiplying extracel-
lularly in artificial medium; (c) that L. pneumophila
multiplying in human monocytes is resistant to killing
by erythromycin and rifampin even at concentrations
of these antibiotics comparable to or higher than peak
blood levels in humans; and (d) that L. pneumophila
inhibited from multiplying in monocytes by erythro-
mycin and rifampin retains its capacity to multiply in
monocytes after the antibiotics are removed from the
medium.
METHODS
Media. Egg yolk buffer (EYB), with (EYB-BSA) or with-
out 1% bovine serum albumin, and RPMI 1640 medium were
prepared or obtained as described previously (1). Buffered
yeast extract (BYE) broth, pH 6.9, was prepared with 5 g/
liter bovine serum albumin fraction V (Reheis Co., Inc.,
Armour Pharmaceutical Co., Phoenix, AZ), 10 g/liter yeast
extract (Difco Laboratories, Detroit, MI), 0.25 g/liter ferric
pyrophosphate soluble (Center for Disease Control, Atlanta,
GA), 0.4 g/liter L-cysteine hydrochloride H20 (Fisher Sci-
entific Co., Pittsburgh, PA), and 10 g/liter N-[2-acetamido]-
2-aminoethane sulfonic acid (ACES) (Sigma Chemical Co.,
St. Louis, MO) essentially as described (12) but with bovine
serum albumin instead of a-ketoglutarate.2
Antibiotics. Erythromycin base suitable for antimicrobial
susceptibility testing (Abbott Diagnostics, Diagnostic Prod-
ucts, North Chicago, IL), 980 jtg activity/mg, was dissolved
' Abbreviations used in this paper: BYE, buffered yeast
extract broth; CFU, colony-forming units; EYB, egg yolk
buffer; EYB-BSA, EYB containing 1% bovine serum albu-
min; MBC, minimal bactericidal concentration; MIC, min-
imal inhibitory concentration.
2 Feeley, J. C. Personal communication.
in methanol, diluted in water to 1,000 Ag activity/ml, and
stored in small aliquots in vials at -70'C. On the day of the
experiments the frozen preparation was thawed and diluted
to the desired concentration in RPMI 1640 medium. Rifam-
pin (Rimactane diagnostic powder, Ciba Pharmaceutical
Company, Summit, NJ), 1,014 ug activity/mg was stored
under vacuum at 40C. On the day of the experiment, the
powder was dissolved in methanol and diluted to the desired
concentration first in water and then in RPMI 1640 medium.
In this paper, the concentrations of antibiotics are stated in
micrograms per milliliter, but refer to micrograms of anti-
biotic activity per milliliter.
Agar. Modified charcoal yeast extract agar was prepared
in 100X15-mm petri dishes (1).
Serum. Venous blood was obtained, clotted, and serum
separated and stored at -70'C until use (13). Normal (non-
immune) human serum (type AB) with an indirect fluores-
cent antibody anti-L. pneumophila titer (14) of <1:64 was
obtained from an adult donor not known tc have ever had
Legionnaires' disease.
Bacteria. L. pneumophila, Philadelphia 1 strain, was
grown in embryonated hens' eggs, harvested, tested for vi-
ability and for the presence of contaminating bacteria, stored
at -70'C, and partially purified by differential centrifu-
gation just before use (1).
Human blood mononuclear cells. Mononuclear cells used
in experiments with L. pneumophila were obtained from
the blood of a normal adult donor not known to have ever
had Legionnaires' disease and with an indirect fluorescent
anti-L. pneumophila antibody titer of <1:64. The mono-
nuclear cell fraction was obtained by centrifugation over a
Ficoll-sodium diatrizoate solution (1); the cells were >99%
viable by trypan blue exclusion. Examination of a stained
cytocentrifuged sample revealed that the mononuclear cell
fraction contained -40% monocytes, 58.5% lymphocytes,
and 1.5% PMN. The adherent subpopulation (containing
>90% monocytes) was prepared as described (1).
Assay for effect of antibiotics on L. pneumophila mul-
tiplication in monocytes. L. pneumophila (1 or 5 X 103
colony-forming units [CFU]/ml) were incubated in 17
X 100-mm plastic tubes (2057, Falcon Labware, Div. Becton,
Dickinson & Co., Oxnard, CA) in 5% C02-95% air with 5
X 106 mononuclear cells in 2 ml RPMI medium containing
15% fresh human serum and either erythromycin in con-
centrations ranging from 0 to 1.25 Ag/ml or rifampin in
concentrations ranging from 0 to 0.01 Mg/ml. The cultures
were incubated on a gyratory shaker (100 rpm) for 1 h and
under stationary conditions thereafter. CFU of L. pneu-
mophila in each culture were determined daily (1). In some
experiments, erythromycin and rifampin were added to cul-
tures immediately after shaking instead of before shaking.
In other experiments, antibiotics were not added until 48 h
after infection when L. pneumophila were in the logarithmic
phase of multiplication in monocytes.
Assay for determining the MIC and minimal bactericidal
concentration (MBC) of erythromycin and rifampin for L.
pneumophila multiplying extracellularly. The MIC and
MBC were determined by modifications of standard meth-
odology (15, 16). L. pneumophila was grown in BYE broth
at 370C on a rotatory shaker to midlogarithmic phase (OD
of 0.400 at 540 nm measured in a Coleman 44 model spec-
trophotometer [Perkin-Elmer Corp., Norwalk, CT]). The cul-
ture was then diluted in BYE broth to two times the con-
centration to be tested; in each experiment, a relatively high
and relatively low concentration of bacteria in the range 7.5
X 104 to 2.5 X 107 CFU/ml were tested. 1 ml of each con-
centration of bacteria to be tested was added to plastic tubes
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containing 1 ml of twofold dilutions of antibiotic in BYE
broth, such that the final concentration of antibiotic ranged
from 0.0312 to 16 ,ug/ml erythromycin and 0.000125 to 1
Mg/ml rifampin. Control tubes contained no antibiotic. Each
concentration of bacteria and antibiotic were tested in trip-
licate. The tubes were sealed and placed horizontally on a
Nutator (Clay-Adams Div., Becton, Dickinson & Co.) and
rotated continuously at 370C for 72 h.
To determine the MIC, the tubes were examined for mac-
roscopic growth at 24, 48, and 72 h by visual inspection and
by measuring the optical density spectrophotometrically.
The MIC was the lowest concentration of antibiotic inhib-
iting macroscopic growth. The results for 24, 48, and 72 h
were the same or within one twofold dilution of each other
in all experiments; only the 48-h value is stated in this paper.
To determine the MBC, tubes with antibiotic concentra-
tions equal to or greater than MIC at 48 h were assayed for
L. pneumophila; samples of each tube's contents were se-
rially diluted in BYE broth and 100 Ml of appropriate di-
lutions spread onto charcoal yeast extract agar plates to de-
termine CFU per milliliter as described (1). The mean CFU
per milliliter for three replicate tubes for each concentration
of bacteria and antibiotic was determined. The MBC was
the lowest concentration of antibiotic that resulted in 23 log
mean decrease in CFU per milliliter from the initial con-
centration (16).
Assay for the effect of preincubation of monocytes with
antibiotics on L. pneumophila multiplication in monocytes.
Mononuclear cells (5 X 106) in 2 ml RPMI 1640 medium
containing 15% fresh human serum were incubated in
17 X 100-mm plastic tubes at 370C in 5% C02-95% air for
48 h with erythromycin (1.25 Mg/ml), rifampin (0.01 Mg/
ml), or without antibiotics. After 48 h, antibiotics were re-
moved by washing leukocytes in all cultures by centrifu-
gation at 200 g for 10 min. The leukocyte pellets were re-
suspended in 2 ml RPMI 1640 medium containing 15% fresh
human serum and incubated with or without antibiotics as
follows. Replicate cultures initially containing erythromycin
were split into two groups; one group was again incubated
with erythromycin (1.25 Mg/ml) and the other group was
incubated without any antibiotic. Similarly, replicate cul-
tures initially containing rifampin were split into two groups;
one group was incubated with rifampin again (0.01 Mg/ml)
and one group without any antibiotic. The replicate cultures
initially containing no antibiotic were incubated again with-
out antibiotic. All cultures were then infected with L. pneu-
mophila (104 CFU/ml) and CFU of L. pneumophila in the
medium were determined daily for 4 d.
Assay for the effect of removal of antibiotics from mono-
cyte cultures infected with L. pneumophila. Mononuclear
cells (5 X 106) in 2 ml RPMI 1640 medium containing 15%
fresh human serum were infected with L. pneumophila (5
X 103 CFU/ml) and incubated for 48 h at 37°C with eryth-
romycin (1.25 Mlg/ml), rifampin (0.01 Mg/ml), or without
antibiotic. After 48 h, the leukocytes and bacteria were
washed by centrifugation at 200 g for 10 min and 1,800 g
for 15 min, and resuspended in RPMI 1640 medium con-
taining 15% fresh human serum. The cultures were then
incubated as follows. Cultures that initially contained anti-
biotic were split into two groups and incubated with or with-
out the antibiotic as in the above assay. The cultures that
initially did not contain antibiotic were incubated again
without antibiotic. CFU of L. pneumophila in the medium
were determined daily for 4 d.
Assay for determining how rapidly antibiotics inhibit the
multiplication of L. pneumophila that are in the logarith-
mic phase of growth in monocytes. Mononuclear cells (5
X 106) were incubated in 35-mm plastic petri dishes (Falcon
Labware) in 2 ml RPMI 1640 medium containing 5% fresh
human serum for 1.5 h at 370C in 5% C02-95% air to allow
monocytes to adhere to the dishes. The monolayers were
washed two times to remove the nonadherent lymphocyte-
enriched fraction of the mononuclear cell population, and
incubated in 2 ml RPMI 1640 medium containing 15% fresh
human serum for 24 h. The monocyte monolayers were then
infected with L. pneumophila and incubated for 24 h at
370C in 5% C02-95% air until the bacteria were at the mid-
logarithmic phase of growth. The replicate monocyte mono-
layers were then vigorously washed three times with RPMI
1640 medium to remove extracellular bacteria. The cultures
were incubated for 0, 1, 4, or 8 h in RPMI 1640 medium
containing 10% fresh human serum and erythromycin (1.25
Mg/ml), rifampin (0.01 Mg/ml), or no antibiotic. At the end
of the incubation, the monocytes were lysed by sonication
and CFU of L. pneumophila were determined.
Electron microscopy. Mononuclear cells were infected
with L. pneumophila and incubated for 48 h until the bac-
teria were in the logarithmic phase of growth in monocytes
as in the "Assay for effect of antibiotics on L. pneumophila
multiplication in monocytes" described above. The cultures
were incubated with erythromycin (1.25 ug/ml), rifampin
(0.01 Mg/ml), or no antibiotic for 1, 4, or 24 h, and processed
for electron microscopy (1).
Assay for determining if concentrations of antibiotics
comparable to peak serum concentrations in humans are
bactericidal for L. pneumophila located intracellularly in
monocytes. Monocyte monolayers in 35-mm petri dishes
were prepared as described in previous assays. The mono-
layers were infected with L. pneumophila and the bacteria
allowed to multiply until they were in the logarithmic phase
of growth. The monocytes were then vigorously washed to
remove extracellular bacteria and 2 ml RPMI 1640 medium
containing 10% fresh human serum added to each petri dish.
Control monocytes were lysed by sonication to prevent fur-
ther growth of L. pneumophila and incubated for 24 h with-
out antibiotics. (During this period, CFU declined 0.30 logs
in experiment 1 and 0.29 logs in experiment 2, Table II).
The other monocytes were incubated for 24 h with 1.25 or
12.5 ug/ml erythromycin or 0.01-100 Mg/ml rifampin and
then lysed by sonication. The bacteria in all cultures were
pelleted by centrifugation two times at 12,000 g (to wash
away antibiotic from cultures treated with them), resus-
pended in 2 ml RPMI 1640 medium, and CFU of L. pneu-
mophila per milliliter determined. Centrifugation resulted
in a loss of 0.24 and 0.17 logs in experiments 1 and 2, re-
spectively, Table II.
Assay for determining bactericidal effect of various con-
centrations of antibiotic on L. pneumophila multiplying
extracellularly in broth. For comparison with the above
assay, concentrations of antibiotic tested against L. pneu-
mophila multiplying intracellularly in that assay were tested
against L. pneumophila multiplying extracellularly in BYE
broth. Midlogarithmic phase broth-grown L. pneumophila
were prepared and added to plastic tubes containing BYE
broth and antibiotic as in the "Assay for determining the
MIC and MBC of erythromycin and rifampin for L. pneu-
mophila multiplying extracellularly" except the final con-
centrations of antibiotic were 1.25 and 12.5 ;g/ml eryth-
romycin and 0.01, 0.02, 0.1, and 1.0 jg/ml rifampin. As a
control for bacterial survival in a medium that does not sup-
port bacterial multiplication, L. pneumophila were added
to plastic tubes containing EYB-BSA. Triplicate tubes were
prepared for each concentration of bacteria and antibiotic.
All tubes were sealed, rotated continuously at 37°C for 24
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h, and CFU per milliliter determined after serial dilution
as in the "Assay for determining the MIC and MBC of eryth-
romycin and rifampin for L. pneumophila multiplying ex-
tracellularly." In the experiment shown in Table III, CFU
per milliliter of L. pneumophila in control tubes containing
EYB-BSA decreased 0.4 log for inoculum A and 1.1 log for
inoculum B.
Sonication of infected monocyte cultures. Monocytes
were lysed by sonication with a 2.54-cm Diam high-gain
disrupter horn attached to a sonicator (Heat Systems Ultra-
sonics, Inc., Plainview, NY). Sonication was performed under
sterile conditions for 10 s continuously with the output con-
trol of the sonicator set at the 4 position. This amount of
sonic energy lysed the leukocytes completely but did not
reduce bacterial CFU (1).
RESULTS
MIC and MBC of erythromycin and rifampin mul-
tiplying extracellularly. We determined the MIC and
MBC of erythromycin and rifampin for the L. pneu-
mophila strain used in this paper (Philadelphia 1
strain) on bacteria multiplying extracellularly in BYE
broth (Methods). The mean MIC for three experi-
ments, each with two concentrations of bacteria, were
0.375 ,g/ml erythromycin and 0.002 Ag/ml rifampin
(Table I). The mean MBC for two experiments, each
with two concentrations of bacteria, were 1 Ag/ml
erythromycin and 0.009 Ag/ml rifampin, higher than
the MIC (Table I). CFU per milliliter were reduced
23 logs at the MBC, but cultures were not sterilized
(Table I).
Erythromycin and rifampin inhibit the intracel-
lular multiplication of L. pneumophila in human
monocytes. We infected mononuclear cell cultures
with L. pneumophila in the presence of 0-1.25 ,ug/ml
erythromycin or 0-0.01 ,ug/ml rifampin and assayed
the culture medium daily for CFU of L. pneumophila
(Methods). L. pneumophila multiplied several logs in
the presence of 0-0.125 Mg/ml erythromycin but mul-
tiplication was completely inhibited by 1.25 ,ug/ml
erythromycin (Fig. 1A). The MIC of erythromycin for
L. pneumophila multiplying in broth was in this range
(Table I).
L. pneumophila multiplied several logs in the pres-
ence of 0 or 0.001 Ag/ml of rifampin, but multipli-
cation was completely inhibited by 0.01 ,g/ml rifam-
pin (Fig. 2A). The MIC of rifampin for L. pneumo-
phila multiplying in broth was also in this range
(Table I).
Erythromycin (1.25 Mg/ml) and rifampin (0.01 ,g/
ml) inhibited L. pneumophila multiplication whether
added to mononuclear cells immediately before or
TABLE I
MIC and MBC of Erythromycin and Rifampin for
L. pneumophila Multiplying Extracellularly
Erythromycin Rifampin
Inoculum of A log CFU/ml A log CFU/ml
Experiment L. pneumophila MIC MBC at MBC MIC MBC at MBC
CFU/mI
1 5.8 X 105 0.25 0.004 - -
7.5 X 104 0.25 - - 0.004 - -
2 2.1 X 107 0.5 1 -3.9 0.002 0.016 -3.8
3.5 X 105 0.25 1 -4.1 0.001 0.016 -5.5
3 2.5 X 107 0.5 1 -3.8 0.002 0.002 -4.4
1.0 X 106 0.5 1 -3.4 0.0005 0.002 -3.8
Mean 0.375 1 0.002 0.009
In three independent experiments, L. pneumophila were grown to midlogarithmic phase in BYE broth and diluted
in BYE broth to twice the concentrations indicated in the column entitled "Inoculum of L. pneumophila"; two
concentrations of bacteria were studied in each experiment. The bacterial suspension was then diluted 50:50 with
BYE broth containing twofold dilutions of antibiotic such that the final concentrations of antibiotic ranged from
0.0312 to 16 &g/ml erythromycin and from 0.000125 to 1 Ag/ml rifampin. All measurements were performed in
triplicate. The MIC was the lowest concentration of antibiotic inhibiting macroscopic growth and was determined
as described in Methods; the values stated are for 48-h incubation in antibiotic-containing BYE broth. The MBC
was determined in experiments 2 and 3. The MBC was the lowest concentration of antibiotic that resulted in .3
log mean decrease in CFU per milliliter for three replicate tubes after 48-h incubation in antibiotic-containing BYE
broth. The mean log decrease in cultures containing the MBC level of antibiotic are stated in the columns entitled
"A log CFU/ml at MBC."
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FIGURE 1 Effect of erythromycin on L. pneumophila multiplication in human monocytes. (A)
Erythromycin inhibits the intracellular multiplication of L. pneumophila. L. pneumophila
(5 X 103 CFU/ml) were incubated at 37°C in 5% C02-95% air with 5 X 106 mononuclear cells
in 2 ml RPMI 1640 medium containing 15% fresh human serum and erythromycin in concen-
trations ranging from 0 to 1.25 gg/ml (Methods). CFU of L. pneumophila in the medium of
each culture were determined daily. Each point represents the mean for two replicate cul-
tures±SEM. (B) Erythromycin inhibits the intracellular multiplication of L. pneumophila that
are in the logarithmic phase of growth in monocytes. Mononuclear cell cultures were prepared,
infected with L. pneumophila, and assayed for CFU daily as in A except that erythromycin
was not added until 48 h after the infection, when the bacteria were in the logarithmic phase
of growth in monocytes. Each point represents the mean for two replicate cultures±SE.
after infection with L. pneumophila (data not pre-
sented).
Erythromycin and rifampin inhibit the intracel-
lular multiplication of L. pneumophila in the loga-
rithmic phase of growth in monocytes. We infected
mononuclear cell cultures with L. pneumophila and
allowed the bacteria to multiply until they were in the
logarithmic phase of growth (Methods). We then
added erythromycin (0-1.25 gg/ml) or rifampin (0-
0.01 ytg/ml) to the cultures. Erythromycin and rifam-
pin inhibited multiplication of midlogarithmic phase
L. pneumophila (Figs. lB and 2B) and at the same
concentrations that were inhibitory to lag phase bac-
teria (Figs. IA and 2A).
Monocytes preincubated with antibiotics do not
inhibit L. pneumophila multiplication after the an-
tibiotics are removed. We preincubated mononuclear
cells for 2 d without antibiotics or with inhibitory con-
centrations of erythromycin (1.25 ,g/ml) or rifampin
(0.01 Ag/ml), washed the cultures to remove the an-
tibiotics, and then infected the monocytes with L.
pneumophila (Methods). L. pneumophila multiplied
as readily in monocytes preincubated with inhibitory
concentrations of erythromycin (Fig. 3A) or rifampin
(Fig. 3B) as in monocytes preincubated without anti-
biotic.
Antibiotic inhibition of L. pneumophila multipli-
cation in monocytes is reversible. To determine if L.
pneumophila that have been inhibited from multiply-
ing in monocytes by erythromycin and rifampin retain
their capacity to multiply upon removal of the anti-
biotics, we infected mononuclear cell cultures and in-
cubated the cultures with inhibitory concentrations of
erythromycin (1.25 gg/ml) or rifampin (0.01 ttg/ml)
for 2 d (Methods). We then washed the cultures to
remove antibiotic and continued the incubation with-























































FIGURE 2 Effect of rifampin on L. pneumophila multiplication in human monocytes. (A)
Rifampin inhibits the intracellular multiplication of L. pneumophila. Mononuclear cell cultures
were infected with L. pneumophila (1 X 103 CFU/ml) and assayed for CFU daily as in Fig.
1A except that the cultures were incubated with rifampin in concentrations ranging from 0
to 0.01 Ag/ml. Each point represents the mean for two replicate cultures±SEM. (B). Rifampin
inhibits the intracellular multiplication of L. pneumophila that are in the logarithmic phase
of growth in monocytes. Mononuclear cells were prepared, infected with L. pneumophila, and
assayed for CFU daily as in A, except that rifampin was not added until 48 h after the infection,
when the bacteria were in the logarithmic phase of growth in monocytes. Each point represents
the mean for two replicate cultures±SE.
out antibiotic (Fig. 4). Control cultures were incubated
either with or without antibiotic throughout the course
of the experiment, i.e., before and after the cultures
were washed.
In cultures incubated with inhibitory concentrations
of erythromycin or rifampin, L. pneumophila multi-
plication was inhibited as in previous experiments
(Fig. 4). When these antibiotics were removed from
the cultures, L. pneumophila multiplied several logs
(Fig. 4).
Thus, L. pneumophila are inhibited from multiply-
ing by erythromycin and rifampin, but these bacteria
retain their capacity to multiply when these antibiotics
are removed.
Erythromycin and rifampin inhibit the intracel-
lular multiplication of L. pneumophila in monocytes
within I h of addition to midlogarithmic phase bac-
teria. To determine how rapidly erythromycin and
rifampin inhibit L. pneumophila multiplication in
monocytes, we infected monocytes in monolayer cul-
ture with L. pneumophila, allowed the bacteria to
multiply until they were in the midlogarithmic phase
of growth, washed the monolayers to remove extra-
cellular bacteria, and added inhibitory concentrations
of erythromycin (1.25 gtg/ml) or rifampin (0.01 Asg/
ml) to the cultures. At 0, 1, 4, and 8 h thereafter, we
lysed the monocytes by sonication, and assayed the
cultures for CFU of L. pneumophila (Methods) (Fig.
5). L. pneumophila multiplication in monocytes was
inhibited within 1 h of addition of erythromycin or
rifampin (Fig. 5).
L. pneumophila multiplication in monocyte cultures
during the first 8 h after infection probably represents
multiplication of only bacteria that remain within the
same monocyte in which they were located at 0 h and
not in addition, multiplication of bacteria that have
burst out of one monocyte and infected another. This
is because (a) in an asynchronous culture, only a lim-
20 M. A. Horwitz and S. C. Silverstein
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FIGURE 3 Monocytes preincubated with antibiotics do not inhibit L. pneumophila multipli-
cation after the antibiotics are removed. Mononuclear cells (5 X 106) were incubated in plastic
tubes in 2 ml RPMI 1640 medium containing 15% fresh human serum at 370C in 5% CO2-95%
air for 48 h without antibiotic or with 1.25 jig/ml erythromycin (A) or 0.01 ;ig/ml rifampin
(B). After 48 h, the cultures were washed to remove antibiotics (Methods). Cultures were then
infected with L. pneumophila (104 CFU/ml) and incubated with or without antibiotics as
follows. Cultures incubated without antibiotic before infection were incubated without anti-
biotic after infection (dotted lines). Cultures incubated with antibiotics before infection were
split into two groups; one group was incubated after infection without antibiotic (dashed lines)
and the other group was incubated after infection with the same antibiotic and at the same
concentration as before infection (solid lines). (Following each line on the figure, '+" indicates
antibiotic present and "-" indicates antibiotic absent before or after infection as indicated.)
CFU of L. pneumophila in the medium were determined daily. Each point represents the
mean for two replicate cultures±SE.
ited proportion of the monocytes are at the burst stage
at any one time and only two doubling times occurred
during the 8-h period of this experiment; thus, few
monocytes were likely to have burst during this ex-
periment; (b) infection of monocytes is very inefficient
at low concentrations of extracellular bacteria (1), as
was the case at time 0 h in this experiment, and even
at high concentrations of extracellular bacteria, infec-
tion of monocytes is inefficient when cultures are held
under stationary conditions and not shaken; thus, rein-
fection was unlikely to occur; and (c) data from other
types of experiments indicate that L. pneumophila do
not begin multiplying for at least 4 h, and usually for
several hours longer, after entry into monocytes; thus,
even if some reinfection did occur, few if any of these
bacteria would have begun multiplying during the 8-
h period of this experiment. For these reasons, the
inhibition of L. pneumophila multiplication in anti-
biotic-treated cultures in this experiment probably
represents inhibition, within 1 h, of bacteria located
within the same vacuole in which they resided at
time 0 h.
Since this experiment measures the effect of eryth-
romycin and rifampin on intracellular bacteria only,
the experiment demonstrates that, at the concentra-
tions used, these antibiotics inhibit L. pneumophila
multiplication but do not kill the bacteria to any great
extent.
L. pneumophila inhibited from multiplying in
monocytes by erythromycin or rifampin appear intact
within membrane-bound cytoplasmic vacuoles. To
examine the effects of inhibitory concentrations of
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FIGURE 4 L. pneumophila inhibited from multiplying in monocytes by erythromycin and
rifampin multiply after the antibiotics are removed. Mononuclear cells (5 X 106) in 2 ml RPMI
1640 medium containing 15% fresh human serum were added to plastic tubes, infected with
L. pneumophila, and incubated for 48 h without antibiotic or with 1.25 Mg/ml erythromycin(A) or 0.01 jig/ml rifampin (B). After 48 h the cultures were washed to remove antibiotics(Methods). Cultures incubated without antibiotic before washing were incubated without an-
tibiotic after washing (dotted lines). Cultures incubated with antibiotics before washing were
split into two groups after washing; one group was incubated without antibiotic (dashed lines)
and the other group was incubated with the same antibiotic as before washing (solid lines).(Following each line on the figure, "+" indicates antibiotic present and "-" indicates antibiotic
absent before or after washing as indicated.) CFU of L. pneumophila in the medium were
determined daily. Each point represents the mean for three replicate cultures±SE.
antibiotics or midlogarithmic phase L. pneumophila
in monocytes, we infected mononuclear cell cultures
with L. pneumophila, allowed the bacteria to multiply
to midlogarithmic phase, and then incubated the cul-
tures for 1, 4, or 24 h with erythromycin (1.25 ,Mg/ml),
rifampin (0.01 gg/ml), or without antibiotic (Meth-
ods). We then examined the cultures by electron mi-
croscopy.
At 1, 4, or 24 h after the addition of antibiotics, L.
pneumophila were found in membrane-bound cyto-
plasmic vacuoles within the monocytes. The bacteria
appeared intact within the vacuoles and did not differ
in appearance from bacteria in control monocytes not
cultured in the presence of antibiotics. In monocytes
treated for 4 h with erythromycin, rifampin, or no
antibiotic, there were no significant differences in the
appearance of vacuoles containing L. pneumophila;
93% of 15 such vacuoles in erythromycin-treated
monocytes, 91% of 33 such vacuoles in rifampin-
treated monocytes, and 88% of 25 such vacuoles in
monocytes not treated with antibiotic were studded
with ribosomelike structures; we have previously de-
scribed this feature of L. pneumophila-infected mono-
cytes (1).
L. pneumophila bacteria multiplying intracellu-
larly in monocytes resist killing by peak serum con-
centrations of erythromycin or rifampin. Whereas
erythromycin at 1.25 ,g/ml and rifampin at 0.01 gg/
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FIGURE 5 Erythromycin and rifampin inhibit the intracel-
lular multiplication of L. pneumophila in monocytes within
1 h of addition to midlogarithmic phase bacteria. Monocyte
monolayers in plastic petri dishes containing 2 ml RPMI 1640
medium and 15% fresh human serum were infected with L.
pneumophila, incubated until the bacteria were in the mid-
logarithmic phase of growth, and vigorously washed to re-
move extracellular bacteria (Methods). The cultures were
then incubated for 0, 1, 4, or 8 h with erythromycin (1.25
g/iml), rifampin (0.01 ,ug/ml), or no antibiotic, as indicated.
At the end of the incubation, the monocytes were lysed by
sonication and CFU of L. pneumophila in the medium were
determined. Each point represents the mean for three rep-
licate cultures±SE.
ml were bacteriostatic but not bactericidal for L. pneu-
mophila multiplying intracellularly in monocytes,
these concentrations of antibiotic were bactericidal for
L. pneumophila multiplying under cell-free condi-
tions in broth. Therefore, we investigated whether
higher concentrations of antibiotics, equal to or greater
than peak serum concentrations in humans, are bac-
tericidal for L. pneumophila located intracellularly in
monocytes.
To examine this issue, we infected monocyte mono-
layers with L. pneumophila and allowed the bacteria
to multiply to midlogarithmic phase. We then washed
replicate cultures of monocytes to remove extracellular
bacteria, and incubated the cultures for 24 h in the
presence of 1.25 or 12.5 ,ug/ml of erythromycin or
0.01-100 ,ug/ml of rifampin. The peak serum concen-
tration of intravenously administered erythromycin is
-10 ,g/ml (17) and the peak serum concentration of
orally administered rifampin is -8 Ag/ml (18). We
omitted antibiotics from control cultures but lysed
them by sonication to prevent further growth of L.
pneumophila during the 24-h incubation. After 24 h,
we lysed the monocyte cultures treated with antibiot-
ics, washed the bacteria free of antibiotics by high-
speed centrifugation, and assayed for CFU of L. pneu-
mophila (Methods).
In erythromycin-treated cultures, CFU were slightly
decreased (0.22-0.36 logs) in comparison with controls
(Table 1I), but there was no significant difference in
CFU between cultures treated with 1.25 ,ug/ml, 1.25
times the MBC for extracellularly multiplying L.
pneumophila and cultures treated with 12.5 iug/ml,
10 times that concentration and a concentration com-
parable to peak serum levels.
In cultures treated with 0.01 Ag/ml of rifampin,
approximately the MBC for extracellularly multiply-
ing L. pneumophila, CFU were only slightly decreased
(0.05 or 0.24 logs) below the control level (Table II).
In cultures treated with higher concentrations of ri-
fampin, CFU were decreased in a dose-response fash-
ion. However, even at a concentration of 100 ug/ml,
10 times the peak serum level, and 10,000 times the
MBC for extracellularly multiplying L. pneumophila,
CFU were reduced by only 1.3-1.7 logs. A control
experiment showed that CFU of L. pneumophila were
not decreased as a result of exposure of bacteria to
high concentrations of rifampin after lysis of the
monocytes or as a result of carry-over of rifampin with
the bacteria through the centrifugation steps. Bacteria
from cultures that had been sonicated and incubated
for 24 h without antibiotics were divided into two
groups and 100 tig/ml rifampin added to one of the
two groups before the centrifugation steps. After cen-
trifugation, there was no difference in the number of
CFU of L. pneumophila in the two groups.
Thus, L. pneumophila resists killing by erythro-
mycin and rifampin even when these antibiotics are
at concentrations equal to or greater than peak serum
concentrations in humans.
By way of comparison, we studied the effect of con-
centrations of antibiotics used in the studies presented
in Table I1 on bacteria multiplying extracellularly
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TABLE II
Effect of Peak Serum Concentrations of Antibiotics on Midlogarithmic Phase L.
pneumophilia Multiplying Intracellularly
CFU of L. pneumophda/ml after 24-h
Concentration incubation with antibiotic preparation A logj
Antibiotic Ag/ml XMBC Expt. i Expt. 2 Expt. 1 Expt. 2
None - 0 1.4±0.3 X 104 6.9±1.2 X 103 -
Erythromycin 1.25 1.25 6.1±0.5 X 103 4.1±0.8 X 103 -0.36 -0.22
12.5 12.5 6.4±0.8 X 103 4.0±0.3 X 103 -0.35 -0.24
Rifampin 0.01 1 1.3±0.2 X 104 4.0±0.4 X 103 -0.05 -0.24
0.02 2 4.8±1.1 X 103 1.9±0.2 X 103 -0.47 -0.56
0.1 10 2.1±0.2 X 103 1.2±0.1 X 103 -0.82 -0.77
1.0 100 9.6±1.5 X 102 5.9±0.4 X 102 -1.2 -1.1
10 1,000 3.3±0.3 X 102 4.0±0.5 X 102 -1.6 -1.2
100 10,000 2.6±0.4 X 102 3.4±0.2 X 102 -1.7 -1.3
Monocyte monolayers were prepared in 35-mm petri dishes, infected with L. pneumophila, and the bacteria allowed to
multiply until they were in the logarithmic phase of growth (Methods). The monolayers were then washed to remove
extracellular bacteria. Control monolayers were lysed by sonication to prevent further growth of L. pneumophila and
incubated for 24 h without antibiotics. The other monolayers were incubated for 24 h with erythromycin (1.25 or 12.5
jug/ml) or rifampin (0.01-100 ug/ml) and then lysed by sonication. The bacteria in all cultures were washed by high-
speed centrifugation to remove antibiotics from those cultures that had been treated with them, and CFU in each culture
were determined as described in Methods. Each point represents the mean for three replicate monocyte cultures±SE. Expt.,
experiment.
Mean MBC, as determined in Table I (1 ug/ml erythromycin and 0.009 Mg/ml rifampin).
I (Log CFU in antibiotic-treated cultures) - (log CFU in control cultures not treated with antibiotics).
TABLE III
Effect of Antibiotics on Midlogarithmic Phase L. pneumophila Multiplying Extracellularly
CFU of L. pneumophila/ml after 24-h
Concentration incubation with antibiotic preparation A log
Antibiotic pg/ml XMBC Inoculum A Inoculum B Inoculum A Inoculum B
None - 0 1.0±.01 X 107 8.6±0.9 X 104 -
Erythromycin 1.25 1 1.4±0.8 X 104 1.9±0.3 X 103 -2.9 -1.7
12.5 12 3.9±0.1 X 103 2.2±0.4 X 10' -3.4 -3.6
Rifampin 0.01 1 1.7±0.1 X 102 6.7±2.7 X 10" -4.8 -4.1
0.02 2 2.0±0.6 X 102 1.0±0 X 10' -4.7 -3.9
0.1 10 1.7±0.5 X 102 3.3±2.7 X 10° -4.8 -4.4
1.0 100 9.3±4.0 X 10' 0 -5.0 - >5.0
For comparison with Table II, concentrations of antibiotic tested against L. pneumophila multiplying intracellularly in
Table II were tested against L. pneumophila multiplying extracellularly in BYE broth. Midlogarithmic phase broth-grown
L. pneumophila were added to plastic tubes containing BYE broth and antibiotic such that the final concentrations of
antibiotic were as indicated in the table and the final concentrations of bacteria were 2.5 X 107 CFU/ml (inoculum A)
and 1.0 X 106 CFU/ml (inoculum B). As a control for bacterial survival in a medium that does not support bacterial
multiplication, inocula A and B were suspended in EYB-BSA. The cultures were incubated 24 h and CFU per milliliter
determined as described in Methods; data are the mean for three replicate tubes±SEM. In control tubes containing bacteria
in EYB-BSA inoculum A decreased 0.4 log to 1.0±0.1 X 107 CFU/ml and inoculum B decreased 1.1 log to 8.6±0.9 X 104
CFU/ml during the 24-h incubation. The log difference between CFU per milliliter in these control cultures and
CFU per milliliter in the antibiotic-treated cultures at the end of the 24-h incubation is given under the column entitled
"A log".
" Mean MBC, as determined in Table I (1 ,ug/ml erythromycin and 0.009 Mg/ml rifampin).
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rather than intracellularly. We incubated midlogarith-
mic phase bacteria for 24 h at 370C in BYE broth con-
taining the concentrations of antibiotics indicated in
Table III. After 24 h, we determined the number of
surviving bacteria and compared this with the number
of surviving bacteria in a control culture incubated for
24 h without antibiotic in a medium that does not
support L. pneumophila multiplication. In contrast to
the situation where L. pneumophila were multiplying
intracellularly (Table II), L. pneumophila multiplying
extracellularly under cell-free conditions were highly
susceptible to killing by erythromycin and rifampin
(Table III); CFU per milliliter were reduced 1.7-3.6
logs below control levels in erythromycin-treated cul-
tures, and 3.9-5 or more logs below control levels in
rifampin-treated cultures.
DISCUSSION
We found that L. pneumophila multiplying intra-
cellularly in human monocytes is inhibited from mul-
tiplying by concentrations of erythromycin and rifam-
pin comparable to those that inhibit L. pneumophila
multiplying extracellularly in artificial medium. How-
ever, L. pneumophila multiplying extracellularly is
killed by relatively low concentrations of these anti-
biotics; the MBC are only three- to fivefold higher then
the MIC. In contrast, L. pneumophila multiplying in-
tracellularly is highly resistant to killing by erythro-
mycin and rifampin even at concentrations compa-
rable to or higher than peak blood levels in humans,
levels 12 times the MBC for erythromycin and 10,000
times the MBC for rifampin.
Several differences between intracellular and extra-
cellular bacteria may account for the disparity in their
susceptibility to antibiotics. Bacteria multiplying ex-
tracellularly are directly exposed to antibiotics and
under standardized physiologic conditions i.e., pH,
osmolality, nutrient concentrations, et cetera, set by
the investigator. Bacteria multiplying intracellularly
are very differently situated; for an antibiotic to be
effective against them, the antibiotic must first enter
the host cell and gain access to the compartment in
which they reside. Even then, whether or not the an-
tibiotic can exert its characteristic antimicrobial effect
is critically dependent upon the physiologic charac-
teristics (e.g., the pH) of the pathogen's environment,
which in turn are dependent upon other aspects of the
host-parasite relationship such as whether the patho-
gen inhibits phagosome-lysosome fusion; L. pneumo-
phila inhibits phagosome-lysosome fusion (19).
In addition to differences in location and environ-
ment, bacteria multiplying intracellularly may differ
from bacteria multiplying extracellularly in their in-
trinsic susceptibility to antibiotics, since these bacteria
differ from each other in other fundamental ways. For
example, L. pneumophila growing extracellularly in
artificial medium differ morphologically from bacteria
growing intracellularly; in contrast to intracellularly
growing bacteria, the extracellularly growing bacteria
tend to form filaments and chains (20). Also, extra-
cellularly grown bacteria have been found to be less
virulent for guinea pigs and chicken embryos than in-
tracellularly grown bacteria (21).
In vivo studies of antibiotic efficacy against L. pneu-
mophila have also yielded results at variance with
those obtained from studies involving L. pneumophila
multiplying on artificial medium. Several antibiotics
active against L. pneumophila growing on artificial
medium have been found to lack efficacy against L.
pneumophila in vivo (8-11). It is noteworthy that one
such antibiotic, penicillin G, was reported by Johnson
et al. (22) to be taken up very poorly by rabbit alveolar
macrophages; in contrast, erythromycin and rifampin,
which are active against L. pneumophila both in vivo
and under cell-free conditions, were taken up readily
by rabbit alveolar macrophages (8-11, 22). In fact,
erythromycin and rifampin were among the few an-
tibiotics tested that were concentrated in rabbit al-
veolar macrophages-erythromycin 20-fold and ri-
fampin twofold (22). Thus, at least in the case of these
three antibiotics to which L. pneumophila grown on
artificial medium is sensitive, there is a good corre-
lation between uptake by rabbit alveolar macrophages
in vitro and efficacy in vivo.
Our earlier work indicates that in vivo, L. pneu-
mophila multiplies only intracellularly (1). If so, then
the present study indicates that in vivo L. pneumo-
phila is resistant to killing by erythromycin and rifam-
pin since both intracellularly multiplying bacteria and
extracellular bacteria that are not multiplying are re-
sistant to killing by these antibiotics. Since L. pneu-
mophila probably multiplies only intracellularly in
vivo, we suspect that the studies reported here of in-
tracellularly multiplying L. pneumophila more likely
reflect the in vivo situation than studies involving L.
pneumophila multiplying extracellularly on artificial
medium.
Our data show that L. pneumophila inhibited by
erythromycin and rifampin retains its capacity to mul-
tiply in monocytes after the antibiotics are removed.
This suggests that, in vivo, host defenses may be nec-
essary to eliminate L. pneumophila bacteria from pa-
tients on antibiotics. Host defenses may also be re-
quired to inhibit multiplication of bacteria that survive
a course of treatment. Previous work from this labo-
ratory indicates that cell-mediated immunity plays a
critical role in limiting the multiplication of L. pneu-
mophila (5, 23). Viewed in this way, the role of an-
tibiotics in Legionnaires' disease may be to suppress
L. pneumophila multiplication long enough for the
Antibiotics Reversibly Inhibit Legionella Intracellular Multiplication 25
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host to develop an effective immune defense against
L. pneumophila.
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